Eurofins Genomics Will Be Conducting Genotyping for up to 5 Million Participants of Our Future Health, UK’s Largest Ever Health Research Programme
Eurofins Genomics is proud to announce its support for Our Future Health, the UK’s largest ever health research programme. Eurofins Genomics will be genotyping five million consenting participants within Our Future Health. This will provide important data that, when combined with other questionnaire and health information, will generate a comprehensive picture of population health in the UK, insights from which will be used to transform the prevention, detection and treatment of diseases.
Our Future Health is the UK’s largest health research programme ever conducted, bringing together the public, charity and private sectors to research disease at an unprecedented scale in the UK.
As one of Europe’s leading providers of genomics services, Eurofins Genomics will conduct the genotyping for the Our Future Health programme. To deliver this service, Eurofins Genomics will establish a dedicated laboratory in the UK, where it will carry out genotyping to identify genetic variations and combinations. Genetic variations such as changes of single building blocks of the DNA are associated with many known diseases. Eurofins Genomics will utilise specifically designed microarray technology with high accuracy and reproducibility to identify hundreds of thousands of genetic variations at a time. The resulting data will then be used to determine disease risks and discover biomarkers for diseases diagnosis and therapeutics.
The goal of the Our Future Health programme is to facilitate the discovery and development of new methods of prevention, early detection and treatment of a wide range of diseases.
Today, 59% of UK citizens aged 65 years or older have two or more serious health conditions, and this statistic has been projected to reach 70% by 2035. With the recruitment of five million adult volunteers, this research programme has the potential to improve the long-term health of millions of people in the UK and globally. The insights gained into links between DNA and diseases through this programme will accelerate the development of innovative solutions to help people to live healthier lives for longer.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. With 58,000 staff across a network of 900 laboratories in 54 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.
Eurofins Shares are listed on Euronext Paris Stock Exchange.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LINTONPHARM27.5.2022 15:02:13 CEST | Press release
LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting
FEELM27.5.2022 13:40:10 CEST | Press release
FEELM unveils the world's first ceramic coil disposable pod solution at Vaper Expo UK 2022
TYAN27.5.2022 09:02:13 CEST | Press release
TYAN Brings Modern HPC Server Platforms for Data Centers at ISC 2022
MAVENIR27.5.2022 09:02:13 CEST | Press release
Mavenir’s Containerized Open vRAN Small Cell Solution Wins Award for Outstanding Contribution to Emerging Technology or Architecture
MA-TAKEDA/SEAGEN26.5.2022 23:27:07 CEST | Press release
Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom